Voyageur Pharmaceuticals ( (TSE:VM) ) has issued an announcement.
Voyageur Pharmaceuticals Ltd. has successfully completed human testing of its Health Canada-licensed barium contrast media products, paving the way for their launch in the Canadian market. The company plans to begin market testing and initial sales in Canada, with further international distribution discussions underway. This development positions Voyageur as a key player in the global contrast media market, focusing on innovation, image quality, and patient safety. The company also plans to initiate phase two testing to support FDA licensing, aiming to expand its market presence and enhance its industry positioning.
More about Voyageur Pharmaceuticals
Voyageur Pharmaceuticals Ltd. is a Canadian public company focused on developing high-performance and cost-effective imaging contrast agents using barium and iodine Active Pharmaceutical Ingredients (API). The company aims to become a key player in the contrast media market by vertically integrating the barium and iodine markets and producing its own materials. Voyageur is committed to sustainability, with plans to implement carbon capture infrastructure and sustainable manufacturing practices. The company owns the Frances Creek barium sulphate project, which provides a high-grade mineral resource for pharmaceutical applications.
Average Trading Volume: 26,921
Technical Sentiment Signal: Sell
Current Market Cap: $20.06M
For a thorough assessment of VM stock, go to TipRanks’ Stock Analysis page.